Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...
Reexamination Certificate
2006-01-31
2006-01-31
Li, Q. Janice (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal in an in vivo...
C800S008000, C800S013000, C800S018000, C800S021000
Reexamination Certificate
active
06992234
ABSTRACT:
Disclosed is a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene. The homozygous FcRn disruption prevents the expression of a functional FcRn protein, resulting in a transgenic knockout mouse in which exogenously administered IgG1 exhibits a substantially shorter half-life, as compared to the half-life of exogenously administered IgG1 in a wild-type mouse. The transgenic knockout mouse with a homozygous FcRn disruption is also unable to absorb maternal IgG in the prenatal or neonatal stage of development. Also disclosed is a transgenic knockout mouse comprising a homozygous FcRn disruption and a human FcRn transgenic. The transgenic addition of human FcRn results in a substantial increase in the half-life of exogenously administered human IgG1. Methods of using the transgenic knockout mouse, and cells derived from them, are also disclosed.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5225539 (1993-07-01), Winter
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5877396 (1999-03-01), Ravetch et al.
patent: 6096871 (2000-08-01), Presta et al.
patent: 6121022 (2000-09-01), Presta et al.
Linder, Lab Animal May 2001;30:34-9.
Nebert et al, Biochemical Pharmacol Feb. 1997;53:249-54.
Mullins et al, J Clin Invest Apr. 1996;97:1557-60.
Logan and Sharma, Clin Exp Pharmacol Physiol Dec. 1999;26:1020-25.
Theofilopolos and Dixon,Adv. Immunol. 37: 269-390 (1985).
Raghavan et al.,Immunity1: 303-315 (1994).
Morel et al.,Immunity1: 219-229 (1994).
Murphy and Roths,Arthritis Rheum. 22: 1188-1194 (1979).
Andrews et al.,J. Exp. Med. 148: 1198-1215 (1978).
Simister and Mostov,Nature337: 184-7 (1989).
Simister et al.,Eur. J. Immunol. 26: 1527-31 (1996).
Ghetie et al.,Eur. J. Immunol. 26: 690-696 (1996).
Ghetie and Ward,Annu. Rev. Immunol. 18: 739-66 (2000).
Brambell et al.,Nature203: 1352-5 (1964).
Brambell, F.W.,Lancet. 2: 1087-93 (1966).
Capecchi, M.R.,Trends Genet. 5: 70-76 (1989).
Israel et al.,Immunology89: 573-578 (1996).
Karlsson et al.,Proc. Natl. Acad. Sci. USA96: 2244-2249 (1999).
Israel et al.,J. of Immun. 154: 6246-6251 (1995).
Zhiya Yu et al., “Mechanism of Intravenous Immune Globulin Therapy in Antibody-Mediated Autoimmune Diseases,” New England Journal of Medicine 340(3):227-228 (1999).
Amos Etzioni et al., “High Dose Intravenous Gammaglobulins in Autoimmune Disorders: Mode of Action and Therapeutic Uses,” Autoimmunity 3:307-315 (1989).
Robert A. Good et al., “Historic Aspects of Intravenous Immunoglobulin Therapy,” Cancer 68:1416-1419 (1991).
Ghetie et al., “Increasing the serum persistence of an IgG fragment by random mutagenesis,” Nature Biotechnology 15:637:640 (1997).
Fish & Neave IP Group Ropes & Gray LLP
Li Q. Janice
The Jackson Laboratory
LandOfFree
FcRn-based therapeutics for the treatment of auto-immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with FcRn-based therapeutics for the treatment of auto-immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FcRn-based therapeutics for the treatment of auto-immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3581336